NovaBridge Secures FDA Alignment for Accelerated Approval Pathway of Givastomig in Gastric Cancer
Summary
NovaBridge Biosciences announced FDA alignment for an accelerated approval pathway for its lead gastric cancer candidate, givastomig, paving the way for a registrational Phase 3 trial in Q4 2026.
Key Events
-
FDA Alignment for Accelerated Approval
The FDA confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer patients.
-
Registrational Phase 3 Trial Planned
NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as a primary endpoint for accelerated approval.
-
Positive Phase 1b Data Underpins Decision
This regulatory milestone builds on robust efficacy and favorable tolerability observed in the Phase 1b combination trial, which showed a 75% objective response rate and 16.9-month median progression-free survival.
Analysis
This 6-K reports a significant regulatory milestone for NovaBridge Biosciences, as the FDA has confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line gastric cancer. This alignment, based on compelling Phase 1b data, de-risks the development process and could expedite market access for a potential first-in-class therapeutic. The company plans to initiate a registrational Phase 3 trial in Q4 2026, which is a critical step towards commercialization.
At the time of this filing, NBP was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.3M. The 52-week trading range was $0.60 to $6.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.